JAM-A Acts via C/EBP-α to Promote Claudin-5 Expression and Enhance Endothelial Barrier Function.
Adult
Aged
Animals
Brain Neoplasms
/ metabolism
CCAAT-Enhancer-Binding Proteins
/ genetics
Capillary Permeability
Cell Adhesion Molecules
/ genetics
Cell Line
Claudin-5
/ genetics
Endothelial Cells
/ metabolism
Female
Glioblastoma
/ metabolism
Humans
Male
Mice, Inbred C57BL
Mice, Knockout
Middle Aged
Neovascularization, Pathologic
Ovarian Neoplasms
/ metabolism
Receptors, Cell Surface
/ genetics
Signal Transduction
Tight Junctions
/ genetics
Up-Regulation
claudin-5
endothelium
junctional adhesion molecule A
tight junctions
vascular permeability
Journal
Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103
Informations de publication
Date de publication:
25 09 2020
25 09 2020
Historique:
pubmed:
17
7
2020
medline:
25
5
2021
entrez:
17
7
2020
Statut:
ppublish
Résumé
Intercellular tight junctions are crucial for correct regulation of the endothelial barrier. Their composition and integrity are affected in pathological contexts, such as inflammation and tumor growth. JAM-A (junctional adhesion molecule A) is a transmembrane component of tight junctions with a role in maintenance of endothelial barrier function, although how this is accomplished remains elusive. We aimed to understand the molecular mechanisms through which JAM-A expression regulates tight junction organization to control endothelial permeability, with potential implications under pathological conditions. Genetic deletion of JAM-A in mice significantly increased vascular permeability. This was associated with significantly decreased expression of claudin-5 in the vasculature of various tissues, including brain and lung. We observed that C/EBP-α (CCAAT/enhancer-binding protein-α) can act as a transcription factor to trigger the expression of claudin-5 downstream of JAM-A, to thus enhance vascular barrier function. Accordingly, gain-of-function for C/EBP-α increased claudin-5 expression and decreased endothelial permeability, as measured by the passage of fluorescein isothiocyanate (FITC)-dextran through endothelial monolayers. Conversely, C/EBP-α loss-of-function showed the opposite effects of decreased claudin-5 levels and increased endothelial permeability. Mechanistically, JAM-A promoted C/EBP-α expression through suppression of β-catenin transcriptional activity, and also through activation of EPAC (exchange protein directly activated by cAMP). C/EBP-α then directly binds the promoter of claudin-5 to thereby promote its transcription. Finally, JAM-A-C/EBP-α-mediated regulation of claudin-5 was lost in blood vessels from tissue biopsies from patients with glioblastoma and ovarian cancer. We describe here a novel role for the transcription factor C/EBP-α that is positively modulated by JAM-A, a component of tight junctions that acts through EPAC to up-regulate the expression of claudin-5, to thus decrease endothelial permeability. Overall, these data unravel a regulatory molecular pathway through which tight junctions limit vascular permeability. This will help in the identification of further therapeutic targets for diseases associated with endothelial barrier dysfunction. Graphic Abstract: An graphic abstract is available for this article.
Identifiants
pubmed: 32673519
doi: 10.1161/CIRCRESAHA.120.316742
pmc: PMC7508279
doi:
Substances chimiques
CCAAT-Enhancer-Binding Proteins
0
CEBPA protein, human
0
CEBPA protein, mouse
0
CLDN5 protein, human
0
Cell Adhesion Molecules
0
Claudin-5
0
Cldn5 protein, mouse
0
F11R protein, human
0
F11r protein, mouse
0
Receptors, Cell Surface
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1056-1073Références
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Blood. 2004 Apr 1;103(7):2744-52
pubmed: 14656889
Haematologica. 2013 Jun;98(6):918-27
pubmed: 23349306
Physiol Rev. 2006 Jan;86(1):279-367
pubmed: 16371600
Acta Neuropathol. 2018 Mar;135(3):311-336
pubmed: 29411111
J Cell Sci. 1997 Sep;110 ( Pt 17):2065-77
pubmed: 9378757
J Cell Biol. 2008 Nov 3;183(3):409-17
pubmed: 18955553
Exp Cell Res. 2004 Oct 15;300(1):202-12
pubmed: 15383327
CNS Neurosci Ther. 2017 Dec;23(12):947-960
pubmed: 28961379
Exp Cell Res. 2003 Nov 1;290(2):275-88
pubmed: 14567987
Physiol Rev. 2004 Jul;84(3):869-901
pubmed: 15269339
J Clin Invest. 2004 Sep;114(5):729-38
pubmed: 15343392
Neurosci Lett. 2020 May 1;726:133664
pubmed: 29966749
Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2408-16
pubmed: 16723450
CNS Neurol Disord Drug Targets. 2014;13(8):1413-26
pubmed: 25345514
J Cell Sci. 2007 Jan 1;120(Pt 1):17-22
pubmed: 17182900
Nat Rev Mol Cell Biol. 2004 Apr;5(4):261-70
pubmed: 15071551
J Biol Chem. 2004 Apr 16;279(16):16254-62
pubmed: 14749337
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
Int J Clin Exp Pathol. 2014 Sep 15;7(10):7242-8
pubmed: 25400822
Ann Surg Oncol. 2012 Dec;19(13):4330-6
pubmed: 22549289
Biochem J. 2002 Aug 1;365(Pt 3):561-75
pubmed: 12006103
Curr Neuropharmacol. 2008 Sep;6(3):179-92
pubmed: 19506719
J Virol. 1998 Nov;72(11):8463-71
pubmed: 9765382
Cold Spring Harb Perspect Med. 2012 Oct 01;2(10):
pubmed: 23028127
Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10634-9
pubmed: 16027360
IEEE Trans Image Process. 1995;4(3):370-8
pubmed: 18289986
J Mol Med (Berl). 2009 Jun;87(6):571-82
pubmed: 19337719
Biochem Biophys Res Commun. 2009 Mar 6;380(2):387-91
pubmed: 19250634
Eur J Cell Biol. 2006 Nov;85(11):1131-44
pubmed: 16959372
Blood. 2004 Apr 15;103(8):3005-12
pubmed: 15070677
J Biol Chem. 2005 Mar 25;280(12):11665-74
pubmed: 15677455
Mol Pharmacol. 2013 Jan;83(1):122-8
pubmed: 23066090
J Neurochem. 2006 May;97(4):922-33
pubmed: 16573646
Eur J Cell Biol. 2000 Oct;79(10):707-17
pubmed: 11089919
Mol Biol Cell. 2009 Apr;20(7):1916-25
pubmed: 19176753
Methods Mol Biol. 2015;1270:321-46
pubmed: 25702127
Int J Gynecol Cancer. 2009 Feb;19(2):208-13
pubmed: 19395995
Biochem Soc Trans. 2008 Apr;36(Pt 2):149-55
pubmed: 18363555
Blood. 2005 Mar 1;105(5):1950-5
pubmed: 15374886
Mol Cell Endocrinol. 2002 Feb 25;188(1-2):15-20
pubmed: 11911941
Ann N Y Acad Sci. 2012 Jun;1257:115-24
pubmed: 22671597
Blood. 2007 Sep 15;110(6):1848-56
pubmed: 17505016
BMC Cell Biol. 2010 Sep 07;11:68
pubmed: 20822540
J Cell Sci. 2000 Jul;113 ( Pt 13):2363-74
pubmed: 10852816
Nat Rev Immunol. 2007 Jun;7(6):467-77
pubmed: 17525755
Mol Med Rep. 2014 Mar;9(3):779-85
pubmed: 24366267
Nat Cell Biol. 2008 Aug;10(8):923-34
pubmed: 18604199
Oncogene. 2017 Sep 14;36(37):5221-5230
pubmed: 28504718
Cell Stem Cell. 2008 Nov 6;3(5):493-507
pubmed: 18983965
Circ Res. 2018 Jan 19;122(2):231-245
pubmed: 29233846
Acta Neuropathol. 2000 Sep;100(3):323-31
pubmed: 10965803
Biochem Biophys Res Commun. 2007 Nov 16;363(2):276-82
pubmed: 17888405
Cell. 1989 Nov 17;59(4):675-80
pubmed: 2573431
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3928-36
pubmed: 17724169
Ups J Med Sci. 2015;120(3):135-43
pubmed: 26220421
J Cell Biol. 1998 Jul 13;142(1):117-27
pubmed: 9660867
Nat Genet. 2001 Mar;27(3):263-70
pubmed: 11242107
Prog Neurobiol. 2018 Feb;161:79-96
pubmed: 29217457
Fluids Barriers CNS. 2012 Nov 09;9(1):23
pubmed: 23140302
Circ Res. 2019 Feb 15;124(4):511-525
pubmed: 30591003
Cell Signal. 2008 Sep;20(9):1608-15
pubmed: 18585005
J Exp Med. 2007 Dec 24;204(13):3067-76
pubmed: 18039951
J Biol Chem. 2008 Mar 14;283(11):6843-53
pubmed: 18195020
J Cell Biol. 2015 Mar 16;208(6):821-38
pubmed: 25753039
J Biol Chem. 2003 Nov 28;278(48):48434-44
pubmed: 12966102
J Cell Biol. 2003 May 12;161(3):653-60
pubmed: 12743111
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Leukoc Biol. 2006 Oct;80(4):714-8
pubmed: 16857733
EMBO Rep. 2011 Apr;12(4):314-20
pubmed: 21372850
J Immunol. 1991 Oct 1;147(7):2122-9
pubmed: 1918946
J Biol Chem. 2009 Jun 26;284(26):17391-403
pubmed: 19423709
J Biol Chem. 2007 May 11;282(19):14515-24
pubmed: 17351296
EMBO Mol Med. 2014 Feb;6(2):239-58
pubmed: 24378569
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8392-6
pubmed: 7690960